VOLATILE COMPOUNDS AS FUNGICIDES (2006)
Clark, Walter L., Leonard, John M.
The vapors of approximately 250 organic compounds were examined for fungus inhibitive properties. The procedure was a petri-dish assay, which, though scarcely comparable to actual tests under service...
NRL Tropical Exposure Facilities (2006)
In the recent war the problem of protecting material from climatic deterioration was accentuated due to the rapid failure of much of the initial equipment consigned to tropical areas. During the war...
THE DENSITY-GRADIENT COLUMN AS A TOOL FOR MEASURING SEA WATER DENSITY. (2005)
Bultman,John D., Leonard,John M.
The possibility of using the density-gradient technique for determining the density of sea water is examined. In this method a water-drop sample falls through a column of immiscible liquid having a...
Inhibitors for Marine Sulfate-Reducing Bacteria in Shipboard Fuel Storage Tanks. (1998)
Klemme,Dorothea E., Leonard,John M.
Problems of corrosive fuels, as well as corrosion of metals, from marine sulfate-reducing bacteria in shipboard fuel tanks continue to plague the Navy. A solution was sought through finding a...
European Scientific Notes, Volume 26, Number 7, (1998)
Leonard,John M., Hewitson,Victoria
The monthly report contains articles-relative to aerospace technology, biological science advancements, structural engineering, computer sciences, physical sciences and microwave technology.
European Scientific Notes. Volume 26, Number 8, (1998)
Leonard,John M., Hewitson,Victoria S.
The report is a monthly publication presenting brief articles concerning recent developments in European scientific research. It is hoped that these articles (which do not constitute part of the...
European Scientific Notes. Volume 26, Number 10, (1998)
Leonard,John M., Hewitson,Victoria
The monthly publication presents brief articles concerning recent developments in European scientific research. It is hoped that these articles (which do not constitute part of the scientific...
European Scientific Notes. Volume 26, Number 11. (1998)
Leonard,John M., Hewitson,Victoria
The monthly publication presents brief articles concerning recent developments in European scientific research. It is hoped that these articles (which do not constitute part of the scientific...
European Scientific Notes. Volume 26, Number 12, (1998)
Leonard,John M., Hewitson,Victoria
See also Volume 26, Number 9, AD-750 267.
A simple relationship between viral load and survival time in HIV-1 infection
Arnaout, Ramy A., Lloyd, Alun L., O’Brien, Thomas R., Goedert, James J., Leonard, John M., Nowak, Martin A.
Despite important recent insights into the short-term dynamics of HIV-1 infection, our understanding of the long-term pathogenesis of AIDS remains unclear. Using an approach that places rapid...
Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers
Hsu, Ann, Granneman, G. Richard, Cao, Guoliang, Carothers, Lori, Japour, Anthony, El-Shourbagy, Tawakol, ...
The pharmacokinetic interaction between indinavir and ritonavir was evaluated in five groups of healthy adult volunteers to explore the potential for twice-daily (b.i.d.) dosing of this combination....
Effect of Fluoxetine on Pharmacokinetics of Ritonavir
Ouellet, Daniele, Hsu, Ann, Qian, Jiang, Lamm, Janet E., Cavanaugh, John H., Leonard, John M., ...
The potential interaction between fluoxetine, a known inhibitor of cytochrome P-450 isoform 2D6 (CYP2D6), and ritonavir, a human immunodeficiency virus type 1 protease inhibitor, was evaluated in...
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
Sham, Hing L., Kempf, Dale J., Molla, Akhteruzammen, Marsh, Kennan C., Kumar, Gondi N., Chen, Chih-Ming, ...
The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using the X-ray...
Carrillo, Alejandro, Stewart, Kent D., Sham, Hing L., Norbeck, Daniel W., Kohlbrenner, William E., Leonard, John M., ...
ABT-378, a new human immunodeficiency virus type 1 (HIV-1) protease inhibitor which is significantly more active than ritonavir in cell culture, is currently under investigation for the treatment of...
Eastman, P. Scott, Mittler, John, Kelso, Reed, Gee, Chris, Boyer, Eric, Kolberg, Janice, ...
Ten subjects received 600 to 1,200 mg of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor ritonavir per day. Following 2 weeks of therapy, plasma HIV RNA levels decreased by a mean...
Thomas, Frank E., Leonard, John M., Alford, Robert H.
Nonpigmented multiply drug-resistant Serratia marcescens caused an extensive outbreak of infection at the Nashville Veterans Administration Hospital. Isolates were of one serotype resistant to all...
A simple relationship between viral load and survival time in HIV-1 infection
Arnaout, Ramy A., Lloyd, Alun L., O’Brien, Thomas R., Goedert, James J., Leonard, John M., Nowak, Martin A.
Despite important recent insights into the short-term dynamics of HIV-1 infection, our understanding of the long-term pathogenesis of AIDS remains unclear. Using an approach that places rapid...
Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers
Hsu, Ann, Granneman, G. Richard, Cao, Guoliang, Carothers, Lori, Japour, Anthony, El-Shourbagy, Tawakol, ...
The pharmacokinetic interaction between indinavir and ritonavir was evaluated in five groups of healthy adult volunteers to explore the potential for twice-daily (b.i.d.) dosing of this combination....
Effect of Fluoxetine on Pharmacokinetics of Ritonavir
Ouellet, Daniele, Hsu, Ann, Qian, Jiang, Lamm, Janet E., Cavanaugh, John H., Leonard, John M., ...
The potential interaction between fluoxetine, a known inhibitor of cytochrome P-450 isoform 2D6 (CYP2D6), and ritonavir, a human immunodeficiency virus type 1 protease inhibitor, was evaluated in...
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
Sham, Hing L., Kempf, Dale J., Molla, Akhteruzammen, Marsh, Kennan C., Kumar, Gondi N., Chen, Chih-Ming, ...
The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using the X-ray...
Carrillo, Alejandro, Stewart, Kent D., Sham, Hing L., Norbeck, Daniel W., Kohlbrenner, William E., Leonard, John M., ...
ABT-378, a new human immunodeficiency virus type 1 (HIV-1) protease inhibitor which is significantly more active than ritonavir in cell culture, is currently under investigation for the treatment of...
Eastman, P. Scott, Mittler, John, Kelso, Reed, Gee, Chris, Boyer, Eric, Kolberg, Janice, ...
Ten subjects received 600 to 1,200 mg of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor ritonavir per day. Following 2 weeks of therapy, plasma HIV RNA levels decreased by a mean...
Thomas, Frank E., Leonard, John M., Alford, Robert H.
Nonpigmented multiply drug-resistant Serratia marcescens caused an extensive outbreak of infection at the Nashville Veterans Administration Hospital. Isolates were of one serotype resistant to all...
Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers
Ouellet, Daniele, Hsu, Ann, Qian, Jiang, Locke, Charles S, Eason, Carolyn J, Cavanaugh, John H, ...
HIV-1 Dynamics In Vivo: Virion Clearance Rate, Infected Cell Lifespan, and Viral Generation Time
Alan S. Perelson, Avidan U. Neumann, Martin Markowitz, John M. Leonard, David D. Ho
Using a new mathematical model to analyze a detailed set of viral load data collected from five infected patients after the administration of a potent inhibitor of HIV-1 protease, it was estimated...
Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection
David D. Ho, Avidan U. Neumann, Alan S. Perelson, Wen Chen, John M. Leonard, Martin Markowitz
In observational studies of HIV-1 pathogenesis to date, increased viral load has been shown to correlate with CD4 lymphocyte depletion and disease progression.$^{1-9}$ However, relatively little...